From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司,专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法,美国食品和药物管理局已接受 CABA-201 的新药申请,为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日,中国南京和上海,美国宾夕法尼亚州费城和加利福尼亚州圣何塞,——驯鹿生物(“IASO Bio”),一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ,一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-22-232575 Act: 34 Size: 178 KB 网页链接
$Cabaletta Bio(CABA)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001019056-22-000570 Act: 34 Size: 154 KB 网页链接
$Cabaletta Bio(CABA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-22-016650 Act: 34 Size: 8 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001193125-22-217960 Act: 34 Size: 14 MB 网页链接
$Cabaletta Bio(CABA)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-22-085691 Act: 34 Size: 163 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-020995 Size: 9 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-020997 Size: 9 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-020998 Size: 9 KB 网页链接
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-22-020999 Size: 9 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, item 5.07 Accession Number: 0001193125-22-165785 Act: 34 Size: 156 KB 网页链接